journal article·2026-06-01Open access

Organobodies: a robust and size-controllable system for generating scalable hiPSC-derived liver organoids for drug toxicity screening

Mostafa Kiamehr, Stefano Manzini, Burak Toprakhisar, Rodrigo F Madeiro da Costa, Guillem García-Llorens, Birhanu Belay, Mustapha Najimi, José V Castell, Wolfgang Moritz, Giulia Chiesa, Katriina Aalto-Setälä, Catherine Verfaillie

Biofabrication· Volume 18· Issue 2

Abstract

Abstract Human hepatic organoids derived from pluripotent or adult stem cells offer powerful platforms for disease modeling and drug discovery. However, developing robust and scalable organoids capable of sustaining long-term functionality remains challenging. Here, we developed a novel, semi-defined approach using a self-assembling peptide and collagen I to create highly uniform human induced pluripotent stem cell-derived hepatic organoids in droplet format, which we term hepatic organobodies (OBs). This method enabled rapid, reproducible production of threedimensional (3D) liver tissues, which remained structurally, metabolically, and functionally stable for several weeks. OBs adopted hallmark hepatic morphology and expressed key hepatocyte genes, several at levels approaching freshly isolated primary human hepatocytes (PHHs). OBs secreted substantially higher albumin and A1AT compared with parallel two dimensional cultures, and transcriptomic profiling revealed marked enhancement of hepatic maturation, including elevated expression of CYP3A4, CYP2C9 , and CYP1A2 , and enrichment of PPAR signaling and fatty acid β -oxidation pathways. Additionally, OBs exhibited drug metabolizing activity comparable to classical Matrigel-based organoids and demonstrated CYP3A4 and CYP2C9 activities comparable to the ‘gold standard’ 3D PHH microtissues. Critically, OBs accurately predicted hepatotoxicity of more than 10 reference compounds, outperforming HepG2 cells and matching PHH-based benchmarks. Overall, we present OBs, a novel, and scalable 3D liver model that delivers advanced maturation and robust metabolic function. This platform offers a powerful and reproducible alternative to existing organoid systems as it avoids animal-derived, undefined matrices such as Matrigel, requires no specialized equipment, and relies on rapid self-curation of the hydrogel triggered by physiological salt concentrations, making the process fast, reproducible, broadly accessible, and scalable.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Analytical Chemistry and Chromatography · thermodynamics and calorimetric analyses · Viral Infectious Diseases and Gene Expression in Insects

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (90)

Show source-provided references
1. Withdrawn—a resource for withdrawn and discontinued drugs10.1093/nar/gkv1192 ↗
2. Mechanisms of drug induced liver injury10.1007/s00018-025-05744-3 ↗
3. Limitations of animal studies for predicting toxicity in clinical trials: part 2: potential alternatives to the use of animals in preclinical trials10.1016/j.jacbts.2020.03.010 ↗
4. Application of new approach methodologies for nonclinical safety assessment of drug candidates10.1038/s41573-025-01182-9 ↗
5. Liver three-dimensional cellular models for high-throughput chemical testing10.1016/j.crmeth.2023.100432 ↗
6. EPA plan to end animal testing splits scientists10.1126/science.365.6459.1231 ↗
7. Human organoids for predictive toxicology research and drug development10.3389/fgene.2021.767621 ↗
8. Modeling development and disease with organoids10.1016/j.cell.2016.05.082 ↗
9. Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids10.1016/j.jhep.2019.06.030 ↗
10. Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids10.1016/j.cmet.2019.05.007 ↗
11. Massive and reproducible production of liver buds entirely from human pluripotent stem cells10.1016/j.celrep.2017.11.005 ↗
12. Generation of uniform liver spheroids from human pluripotent stem cells for imaging-based drug toxicity analysis10.1016/j.biomaterials.2020.120529 ↗
13. Development of a cost-effective automated platform to produce human liver spheroids for basic and applied research10.1088/1758-5090/abbdb2 ↗
14. 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing10.1016/j.biomaterials.2012.11.029 ↗
15. Characterization of a commercially available line of iPSC hepatocytes as models of hepatocyte function and toxicity for regulatory purposes10.1016/j.vascn.2021.107083 ↗
16. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types10.1002/bit.10655 ↗
17. Challenges for the applications of human pluripotent stem cell-derived liver organoids10.3389/fcell.2021.748576 ↗
18. Human pluripotent stem cell-derived organoids as models of liver disease10.1053/j.gastro.2020.06.010 ↗
19. A human liver organoid screening platform for DILI risk prediction10.1016/j.jhep.2023.01.019 ↗
20. Self-assembling peptides: from design to biomedical applications10.3390/ijms222312662 ↗
21. Dynamic reassembly of peptide RADA16 nanofiber scaffold10.1073/pnas.0407843102 ↗
22. Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane10.1073/pnas.90.8.3334 ↗
23. Three-dimensional primary hepatocyte culture in synthetic self-assembling peptide hydrogel10.1089/tea.2007.0143 ↗
24. The 3-D culture and in vivo growth of the human hepatocellular carcinoma cell line HepG2 in a self-assembling peptide nanofiber scaffold10.1155/2010/437219 ↗
25. Differentiation of human neural progenitor cells in functionalized hydrogel matrices10.1089/biores.2012.0209 ↗
26. Self-assembling peptide nanofiber scaffolds for 3-D reprogramming and transplantation of human pluripotent stem cell-derived neurons10.1021/acsbiomaterials.6b00156 ↗
27. Three-dimensional growth matrix for human embryonic stem cell-derived neuronal cells10.1002/term.1512 ↗
28. Transforming growth factor-β1-loaded RADA-16 hydrogel scaffold for effective cartilage regeneration10.1016/j.colsurfb.2024.113959 ↗
29. Amino acid levels determine metabolism and CYP450 function of hepatocytes and hepatoma cell lines10.1038/s41467-020-15058-6 ↗
30. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors10.1016/j.cell.2006.07.024 ↗
31. Generation and characterization of human induced pluripotent stem cells
32. Lipidomic profiling of patient-specific iPSC-derived hepatocyte-like cells10.1242/dmm.030841 ↗
33. Directed differentiation of pluripotent stem cells to functional hepatocytes10.1007/978-1-62703-348-0_11 ↗
34. hiPSC-derived hepatocytes closely mimic the lipid profile of primary hepatocytes: a future personalised cell model for studying the lipid metabolism of the liver10.1002/jcp.27131 ↗
35. Determination of major human cytochrome P450s activities in 96-well plates using liquid chromatography tandem mass spectrometry10.1016/j.tiv.2007.03.022 ↗
36. GENCODE: reference annotation for the human and mouse genomes in 202310.1093/nar/gkac1071 ↗
37. STAR: ultrafast universal RNA-seq aligner10.1093/bioinformatics/bts635 ↗
38. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads10.1093/nar/gkz114 ↗
39. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq210.1186/s13059-014-0550-8 ↗
40. Waskom. Seaborn: statistical data visualization10.21105/joss.03021 ↗
41. Array programming with NumPy10.1038/s41586-020-2649-2 ↗
42. Pandas-dev/pandas: pandas10.5281/zenodo.13819579 ↗
43. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest10.1093/nar/gkac1000 ↗
44. reString: an open-source Python software to perform automatic functional enrichment retrieval, results aggregation and data visualization10.1038/s41598-021-02528-0 ↗
45. Bile acid-FXR signaling facilitates the long-term maintenance of hepatic characteristics in human iPSC-derived organoids10.1016/j.celrep.2025.115675 ↗
46. Mass generation and long-term expansion of hepatobiliary organoids from adult primary human hepatocytes10.1101/2024.06.10.598262 ↗
47. 9-cis-retinoic acid improves disease modelling in iPSC-derived liver organoids10.3390/cells14130983 ↗
48. 2026 Drug induced liver injury rank (DILIrank) dataset
49. Intermittent starvation extends the functional lifetime of primary human hepatocyte cultures10.1093/toxsci/kfaa003 ↗
50. Next generation organoids for biomedical research and applications10.1016/j.biotechadv.2017.10.005 ↗
51. Long-term expansion of functional human pluripotent stem cell-derived hepatic organoids10.15283/ijsc20060 ↗
52. Long-term expansion of functional mouse and human hepatocytes as 3D organoids10.1016/j.cell.2018.11.013 ↗
53. A murine tumor producing a matrix of basement membrane10.1084/jem.145.1.204 ↗
54. Human iPS derived progenitors bioengineered into liver organoids using an inverted colloidal crystal poly (ethylene glycol) scaffold10.1016/j.biomaterials.2018.07.043 ↗
55. A versatile biosynthetic hydrogel platform for engineering of tissue analogues10.1002/adhm.201900979 ↗
56. Cellulose nanofibril hydrogel promotes hepatic differentiation of human liver organoids10.1002/adhm.201901658 ↗
57. Gelatin-based hybrid hydrogels as matrices for organoid culture10.1021/acs.biomac.2c01496 ↗
58. A chemically defined hydrogel for human liver organoid culture10.1002/adfm.202000893 ↗
59. Mechano-modulatory synthetic niches for liver organoid derivation10.1038/s41467-020-17161-0 ↗
60. Liver-on-micropillar: a humanized, animal-free platform for high-throughput assessment of drug-induced liver injury10.1088/1758-5090/ae1063 ↗
61. Advancing hepatotoxicity assessment: current advances and future directions10.1007/s43188-025-00289-w ↗
62. Development of human pluripotent stem cell-derived hepatic organoids as an alternative model for drug safety assessment10.1016/j.biomaterials.2022.121575 ↗
63. Efficient hepatocyte differentiation of primary human hepatocyte-derived organoids using three dimensional nanofibers (HYDROX) and their possible application in hepatotoxicity research10.1038/s41598-024-61544-y ↗
64. Self-assembly behaviors of molecular designer functional RADA16-I peptides: influence of motifs, pH, and assembly time10.1088/1748-605X/12/1/015007 ↗
65. Designer self-assembling peptide nanofiber scaffolds for adult mouse neural stem cell 3-dimensional cultures10.1371/journal.pone.0000119 ↗
66. Primary hepatocyte cultures for pharmaco-toxicological studies: at the busy crossroad of various anti-dedifferentiation strategies10.1007/s00204-012-0983-3 ↗
67. Nanofibrillar cellulose hydrogel promotes three-dimensional liver cell culture10.1016/j.jconrel.2012.06.039 ↗
68. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration10.1038/nature11826 ↗
69. Scalable production of uniform and mature organoids in a 3D geometrically-engineered permeable membrane10.1038/s41467-024-53073-z ↗
70. Core-shell microcapsules: biofabrication and potential applications in tissue engineering and regenerative medicine10.1039/d1bm01974k ↗
71. Alginate microencapsulation for three-dimensional in vitro cell culture10.1021/acsbiomaterials.0c00457 ↗
72. Human iPSC-derived 3D hepatic organoids in a miniaturized dynamic culture system10.3390/biomedicines11082114 ↗
73. Microencapsulated hepatocytes differentiated from human induced pluripotent stem cells: optimizing 3D culture for tissue engineering applications10.3390/cells12060865 ↗
74. Engraftment of human induced pluripotent stem cell-derived hepatocytes in immunocompetent mice via 3D co-aggregation and encapsulation10.1038/srep16884 ↗
75. Nanofibers and their applications in tissue engineering10.2147/nano.2006.1.1.15 ↗
76. Optimization of extracellular matrix for primary human hepatocyte cultures using mixed collagen-Matrigel matrices10.17179/excli2022-5459 ↗
77. The microfluidic environment reveals a hidden role of self-organizing extracellular matrix in hepatic commitment and organoid formation of hiPSCs10.1016/j.celrep.2020.108453 ↗
78. Review article: the signalling and functional role of the extracellular matrix in the development of liver fibrosis10.1111/apt.15773 ↗
79. Collagen biology and non-invasive biomarkers of liver fibrosis10.1111/liv.14390 ↗
80. The liver fibrosis niche: novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix10.1016/j.fct.2020.111556 ↗
81. Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver10.1136/gut.2009.182345 ↗
82. One-step synthesis of composite hydrogel capsules to support liver organoid generation from hiPSCs10.1039/d0bm01085e ↗
83. A high-throughput microfluidic platform for functional hiPSC-derived liver organoids with bile duct- and lobule-like structures10.1039/d5lc00154d ↗
84. Droplet-engineered organoids recapitulate parental tissue transcriptome with inter-organoid homogeneity and inter-tumor cell heterogeneity10.1016/j.fmre.2022.05.018 ↗
85. Self-organized vascularized hepatic organoids in microcapsules for liver regeneration10.34133/research.0898 ↗
86. Scalable production of tissue-like vascularized liver organoids from human PSCs10.1038/s12276-023-01074-1 ↗
87. The nanomechanical signature of liver cancer tissues and its molecular origin10.1039/c5nr02192h ↗
88. Clinical use of the self-assembling peptide RADA16: a review of current and future trends in biomedicine10.3389/fbioe.2021.679525 ↗
89. Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects10.1038/s41598-021-96590-3 ↗
90. CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms10.7717/peerj.18636 ↗